Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy

Patent metadata

Field	Value
Publication number	US-12048682-B2
Application number	US-202217855327-A
Country	US
Kind code	B2
Filing date	Jun 30, 2022
Priority date	Apr 13, 2018
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

First claim

What is claimed is:

1. A method for treating a cancer in a subject in need thereof, the method comprising:
performing a first step, wherein the first step comprises administering to the subject dimethylamino micheliolide (DMAMCL) and a pharmaceutically acceptable carrier; and
performing a second step, wherein the second step comprises exposing at least a portion of the subject to ionizing irradiation energy.

2. The method of claim 1 , wherein administering the DMAMCL comprises administering a nanoparticle selected from the group consisting of a polymeric micelle, a liposome, a dendrimer, an organic-based nanoparticle, a nanoscale coordination polymer particle, a nanoscale metal-organic framework particle, and an inorganic nanoparticle, wherein the DMAMCL is sequestered in the nanoparticle.

3. The method of claim 1 , wherein the ionizing irradiation energy is X-rays or protons.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of a skin cancer, a connective tissue cancer, an adipose cancer, a breast cancer, a head and neck cancer, a lung cancer, a stomach cancer, a pancreatic cancer, an ovarian cancer, a cervical cancer, a uterine cancer, an anogenital cancer, a kidney cancer, a bladder cancer, a colon cancer, a prostate cancer, a central nervous system cancer, a retinal cancer, a blood cancer, a neuroblastoma, multiple myeloma, and a lymphoid cancer.

5. The method of claim 1 , wherein the method further comprises administering to the subject an additional treatment selected from immunotherapy, surgery, chemotherapy, toxin therapy, cryotherapy and gene therapy.

6. The method of claim 5 , wherein the additional treatment comprises immunotherapy.

7. The method of claim 6 , wherein the immunotherapy comprises administering to the subject an immune checkpoint inhibitor.

8. The method of claim 7 , wherein the immune checkpoint inhibitor is selected from the group consisting of a programmed death ligand 1 inhibitor and an indoleamine-2,3-dioxygenase inhibitor.

9. A method for treating a cancer in a subject in need thereof, the method comprising:
administering to the subject dimethylamino micheliolide (DMAMCL) and a pharmaceutically acceptable carrier;
administering to the subject a chemotherapeutic agent; and
exposing at least a portion of the subject to ionizing irradiation energy.

10. The method of claim 9 , wherein administering to the subject DMAMCL comprises administering to the subject a nanoparticle selected from the group consisting of a polymeric micelle, a liposome, a dendrimer, an organic-based nanoparticle, a nanoscale coordination Polymer particle, a nanoscale metal-organic framework particle, and an inorganic nanoparticle, wherein the DMAMCL is sequestered in the nanoparticle.

11. The method of claim 9 , wherein the cancer is selected from the group consisting of a skin cancer, a connective tissue cancer, an adipose cancer, a breast cancer, a head and neck cancer, a lung cancer, a stomach cancer, a pancreatic cancer, an ovarian cancer, a cervical cancer, a uterine cancer, an anogenital cancer, a kidney cancer, a bladder cancer, a colon cancer, a prostate cancer, a central nervous system cancer, a retinal cancer, a blood cancer, a neuroblastoma, multiple myeloma, and a lymphoid cancer.

12. The method of claim 9 , wherein the method further comprises administering to the subject an immunotherapeutic agent.

13. The method of claim 12 , wherein the immunotherapeutic agent is an immune checkpoint inhibitor.

14. The method of claim 9 , wherein the method further comprises administering to the subject one or more of surgery, toxin therapy, cryotherapy and gene therapy.

15. The method of claim 1 , wherein the administering of the first step is performed via oral administration, parenteral administration, or via administration directly to a tumor.

16. The method of claim 9 , wherein the administering of the first step is performed via oral administration, parenteral administration, or via administration directly to a tumor.

Assignees

• Univ Chicago

Inventors

• Lin Wenbin
• Chan Christina
• Han Wenbo

Classifications

• A61K47/6803

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title